Endothelin and pulmonary arterial hypertension

Seminars in Arthritis and Rheumatism

Volumn 34, Issue 1, 2004, Pages 442-453

  Braun Moscovici, Yolanda ^a   Nahir, A Menahem ^a,b   Balbir Gurman, Alexandra ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

bosentan; endothelin; endothelin receptor antagonist; Pulmonary hypertension

Indexed keywords

BERAPROST; BOSENTAN; ENDOTHELIN; ILOPROST; PROSTACYCLIN; SILDENAFIL; UNIPROST; VASODILATOR AGENT;

CLINICAL FEATURE; COUGHING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; FLUSHING; HEADACHE; HEART DISEASE; HUMAN; LIVER DISEASE; LUNG DISEASE; MEDLINE; PATHOGENESIS; PRIORITY JOURNAL; PUBLICATION; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

EID: 4043113533     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2003.11.003     Document Type: Article

References (90)

1. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., et al. The human endothelin family Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 86:1989;2864-2867
2. Yanagisawa M., Kurihara H., Kimura S., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415
3. Ergul A. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Pharmacotherapy. 22:2002;54-65
4. Haynes W.G., Webb D.J. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 16:1998;1081-1098
5. Wagner O.F., Christ G., Wojta J., Vierhapper H., Parzer S., Nowotny P.J., et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 267:1992;1606-1608
6. McArthur H., Warner T.D., Wood E.G., Corder R., Vane J.R. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun. 200:1994;395-400
7. Malek A., Izumo S. Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Am J Physiol. C263:1992;389-396
8. Wesson D., Simoni J., Green D.F. Reduced extracellular pH increases endothelin-1 secretion by human renal micro-vascular endothelial cells. J Clin Invest. 101:1998;578-583
9. Maeda S., Miyauchi T., Sakai S., Kobayashi T., Iemitsu M., Goto K., et al. Prolonged exercise causes an increase in endothelin-1 production in the heart in rats. Am J Physiol. H275:1998;2105-2112
10. Rakugi H., Tabuchi Y., Nakamaru M., Nagano M., Higashimori K., Mikami H., et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun. 169:1990;973-977
11. Boulanger C.M., Tanner F.C., Bea M.L., Hahn A.W., Werner A., Luscher T.F. Oxidized low-density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 70:1992;1191-1197
12. Hattori Y., Kasai K., Nakamura T., Emodo T., Shimoda S.I. Effects of glucose and insulin on immunoreactive endothelin-1 release from cultured bovine endothelial cells. Metabolism. 40:1991;165-169
13. Boulanger C.M., Luscher T.F. Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta. Circ Res. 68:1991;1768-1772
14. Imai T., Hirata Y., Emori T., Yanagisawa M., Masaki T., Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 19:1992;753-757
15. Matsuura A., Yamochi W., Hirata K., Kawashima S., Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension. 32:1998;89-95
16. Woods M., Mitchell J.A., Wood E.G., Barker S., Walcot N.R., Rees G.M., et al. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells evidence for intracellular converting enzyme. Mol Pharmacol. 55:1999;902-909
17. Woods M., Wood E.G., Mitchell J.A., Warner T.D. Signal transduction pathways in cytokine stimulation endothelin-1 release from human vascular smooth muscle cells. J Cardiovasc Pharmacol. 36:2000;S407-S409
18. Stewart D.J., Cernacek P., Mohamed F., Blais D., Cianflone K., Monge J.C. Role of cyclic nucleotides in the regulation of endothelin-1 production by human endothelial cells. Am J Physiol. 266:1994;H944-H951
19. Fujisaki H., Ito H., Hirata Y., Tanaka M., Hata M., Lin M., et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest. 96:1995;1059-1065
20. Rubanyi G.M., Polokoff M.A. Endothelins Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 46:1994;325-415
21. Webb M.L., Meek T.D. Inhibitors of endothelin. Med Res Rev. 17:1997;17-67
22. Yang Z., Richard V., von Segesser L., Bauer E., Stulz P., Turina M., et al. Threshold concentrations of endothelin-1 potentiates contractions to norepinephrine and serotonin in human arteries. Circulation. 82:1990;182-195
23. Thomas P.B., Liu E.C.K., Webb M.L., Mukherjee R., Spinale F.G. Evidence of the endothelin-1 autocrine loop in cardiac myocytes Relation to contractile function with congestive heart failure. Am J Physiol. 40:1996;H2629-H2673
24. Kiowski W., Sutsch G., Hunziker P., Muller P., Kim J., Oechslin E., et al. Evidence of endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736
25. Krum H., Viskoper R.J., Lacourciere Y., Budde M., Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 338:1998;784-790
26. Stewart D.J., Levy R.D., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension marker or mediator of disease? Ann Intern Med. 114:1991;464-469
27. Agui T., Xin X., Cai Y. Stimulation of interleukin-6 production by endothelin in rat bone marrow-derived stromal cells. Blood. 84:1994;2531-2538
28. Hofman F.M., Chen P., Jeyaseelan R. Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells. Blood. 92:1998;3064-3072
29. Peifley K.A., Winkles J.A. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem Biophys Res Commun. 242:1998;202-208
30. Xu S.-W., Denton C.P., Dashwood M.R., Abraham D.J., Black C.M. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol. 31:(suppl 1):1998;S545-S547
31. Kahaleh M.B. Endothelin, an endothelian dependent vasoconstrictor in sclerderma Enhanced production and profibrotic action. Arthritis Rheum. 34:1991;978-983
32. Dubin D., Pratt R.E., Kooke J.P., Dzau V.J. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vas Biol Med. 1:1989;150-154
33. Mansoor A.M., Honda M., Saida K., Ishinaga Y., Kuramochi T., Maeda A., et al. Endothelin-induced collagen remodeling in experimental pulmonary hypertension. Biochem Biophys Res Commun. 215:1995;981-986
34. Knofler R., Urano T., Malyszko J. In vitro effect of endothelin-1 on collagen, and ADP-induced aggregation in human whole blood and platelet rich plasma. Thromb Res. 77:1995;69-78
35. Rubin L. Primary pulmonary hypertension. N Engl J Med. 336:1997;111-117
36. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension Results from a national prospective registry. Ann Intern Med. 115:1991;343-349
37. Rich S. Executive summary from the World Symposium on Primary Pulmonaty Hypertension 1998. 2002;. Available at: http://www.who.int/ncd/chd/pph.html. Accessed July 8
38. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 107:1987;216-223
39. Humbert M., Nunes H., Sitbon O., Parent F., Herve P., Simonneau G., et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med. 22:2001;459-475
40. Stupi A.M., Steen V.D., Owens G.R., Barnes E.L., Rodnan G.P., Medsger T.A. Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 29:1986;515-524
41. Shen J.Y., Chen S.L., Wu Y.X., Tao R.Q., Gu Y.Y., Bao C.D., et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int. 18:1999;147-151
42. Tanaka E., Harigai M., Tanaka M., Kawaguchi Y., Hara M., Kamatani N. Pulmonary hypertension in systemic lupus erythematosus Evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol. 29:2002;282-287
43. Pan T.L., Thumboo J., Boey M.L. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus. 9:2000;338-342
44. Newman J.H., Wheeler L., Lane K.B., Loyd E., Gaddipati R., Phillips J.A., et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 345:2001;319-324
45. Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M., Elliott G.C., et al. Sporadic primary pulmonary hypertension is associated with germ-line mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 37:2000;741-745
46. Hoeper M.M., Galie N., Simonneau G., Rubin L.J. New treatment for pulmonary hypertension. Am J Respir Crit Care Med. 165:2002;1209-1216
47. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 328:1993;1732-1739
48. Dupuis J., Cernacek P., Tardif J.C., Stewart D.J., Gosselin G., Dyrda I., et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J. 135:1998;614-620
49. Voelkel N.F., Hoeper M., Maloney J., Tuder R.M. Vascular endothelial growth factor in pulmonary hypertension. Ann N Y Acad Sci. 796:1996;186-193
50. Dorfmuller P., Zarka V., Durand-Gasselin I., Monti G., Babanian K., Garcia G., et al. Chemokine RANTES in severe pulmonary hypertension. Am J Respir Crit Care Med. 165:2002;535-539
51. Yock P., Popp R. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 70:1984;657-662
52. Morgan J.M., McCormack D.G., Griffiths M.J., Morgan C.J., Barnes P.J., Evans T.W. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation. 84:1991;1145-1149
53. Jolliet P., Bulpa P., Thorens J.B., Ritz M., Chevrolet J.C. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension Predictive ability and consequences on haemodynamics and gas exchange. Thorax. 52:1997;369-372
54. Koh E.R., Lee P., Gladman D.D., Abu-Shakra M. Pulmonary hypertension in systemic sclerosis An analysis of 17 patients. Br J Rheumatol. 35:1996;989-993
55. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 327:1992;76-81
56. Barst R.J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest. 89:1986;497-503
57. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., Frye R.L. Primary pulmonary hypertension Natural history and the importance of thrombosis. Cirulation. 70:1984;580-587
58. Rubin L.J., Mendoza J., Hood M., McGoon M., Barst R., Williams W.B., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 112:1990;485-491
59. Primary Pulmonary Hypertension Study Group, Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 334:1996;296-302
60. Badesch D.B., Tapson V.F., McGoon M.D., Brundage B.H., Rubin L.J., Wigley F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease a randomized controlled trial. Ann Intern Med. 132:2000;425-434
61. Galie N., Manes A., Branzi A. Medical therapy of pulmonary hypertension The prostacyclins. Clin Chest Med. 22:2001;529-537
62. Simonneau G., Barst R.J., Galie N., Naeije R., Rich S., Bourge R.C., et al. Treprostinil Study Group. Continuous subcutaneous infusions of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension A double-blind randomized controlled trial. Am J Respir Crit Care Med. 165:2002;800-804
63. Nagaya N., Uematsu M., Okano Y., Kyotani S., Sakamaki F., Nakanishi F., et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 34:1999;1188-1192
64. Olschewski H., Walmrath D., Schermely R., Ghofrani A., Grimminger F., Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 124:1996;820-824
65. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naije R., Rubin L.J., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 347:2002;322-329
66. Hoeper M.M., Schwarze M., Ehlerding S., Adler-Schuermeyer A., Spiekerkoetter E., Niedermeyer J., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 342:2000;1866-1870
67. Galie N., Humbert M., Vachiery J.L., Vizza C.D., Kneussl M., Manes A., et al. Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension a randomized, double-blind, placebo controlled trial. J Am Coll Card. 39:2002;1496-1502
68. Prasad S., Wilkinson J., Gatzoulis M.A. Sildenafil in primary pulmonary hypertension. N Engl J Med. 343:2000;1342-1345
69. Wilkens H., Guth A., Koenig J., Forestier N., Cremers B., Hennen B., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 104:2001;1218-1222
70. Ghofrani H.A., Wiedemann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., et al. Combined treatment with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 136:2002;515-522
71. Nagaya N., Uematsu M., Oya H., Sato N., Sakamaki F., Kyotani S., et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 163:2001;887-891
72. Williamson D.J., Wallman L.L., Jones R., Keogh A.M., Scroope F., Penny R., et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 102:2000;411-418
73. Sutsch G., Bertel O., Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther. 10:1996;717-725
74. Seed A., Love M.P., McMurray J.J. Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Fail Rev. 6:2001;317-323
75. Torre-Amione G., Yong J.B., Durand J., Bozkurt B., Mann D.L., Kobrin I. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III and IV congestive heart failure. Circulation. 103:2001;973-980
76. Spieker L.E., Mitrovic V., Noll G., Pacher R., Schulze M.R., Muntwyler J., et al. Acute hemodynamic and neurohumoral effects of selective ET (A) receptor blockade in patients with congestive heart failure. J Am Coll Cardiol. 35:2000;1745-1752
77. Filep J.G., Fournier A., Foldes-Filep E. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung Involvement of ET-a and ET-b receptors. Br J Pharmacol. 115:1995;227-236
78. Park S.H., Saleh D., Giaid A., Michel R.P. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of endothelin receptor antagonist. Am J Respir Crit Care Med. 156:1997;600-608
79. Chen S.J., Chen Y.F., Meng Q.C., Durand J., Dicarlo V.S., Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol. 79:1995;2122-2131
80. Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A., Tapson V.F., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension a randomized placebo-controlled study. Lancet. 358:2001;1119-1123
81. Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., et al. Clinical correlates and prognostic significance of 6-minute walk test in patients with primary pulmonary hypertension comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 161:2000;481-492
82. Sitbon O., Badesch D.B., Channick R.N., Frost A., Robbins I.M., Simonneau G., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. A 1-year follow-up study. Chest. 124:2003;247-254
83. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 346:2002;896-903
84. Black C.M. Effects of the oral endothelial receptor antagonist bosentan in a sub-group of patients with pulmonary artery hypertension related to scleroderma (abstr.). Ann Rheum Dis. 61:(suppl 1):2002;109-110
85. Barst R.J., Ivy D., Dingemanse J., Widlitz A., Schmitt K., Doran A., et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary artery hypertension. Clin Pharmacol Ther. 73:2003;372-382
86. Wilkens H., Bauer M., Forestier N., Konig J., Eichler A., Schneider S., et al. Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension. Circulation. 107:2003;1509-1517
87. Hoeper M.M., Taha N., Bekjarova A., Gatzke R., Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J. 22:2003;330-334
88. Kanyon K.W., Nappi J.M. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 37:2003;1055-1062
89. Tilton R.G., Munsch C.L., Sherwood S.J., Chen S.J., Chen Y.F., Wu C., et al. Attenuation of pulmonary vascular hypertension and cardiac hyperthrophy with sitaxsentan sodium, an orally active ET (A) receptor antagonist. Pulmonary Pharmacol Ther. 13:2000;87-97
90. Barst R.J., Rich S., Widlitz A., Horn E.M., McLaughlin V., McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest. 121:2002;1860-1868